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Key pathophysiologic mechanisms of diabetes-related coronary disease include
inflammation and a prothrombotic state. In the setting of non-ST-segment elevation
acute coronary syndromes diabetic patients are at high risk for subsequent cardiovas-
cular events. At the same time, they derive greater benefit than non-diabetic
counterparts from aggressive antithrombotic therapy, early coronary angiography,
and stent-based percutaneous coronary intervention. The mainstays of antithrom-
botic therapy for diabetic patients undergoing percutaneous revascularization include
aspirin, clopidogrel, platelet glycoprotein IIb/IIIa receptor antagonists, and heparin or
low-molecular-weight heparin. Despite dramatic reduction in restenosis conferred by
drug-eluting stents, diabetic patients remain at increased risk for repeat revascular-
ization. More efforts are needed both in terms of local drug elution as well as systemic
pharmacologic therapies to further contain the excessive neointimal proliferation
that characterizes the diabetic response to vascular injury.
© 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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Introduction
It is estimated that sixteen million people in the US have
diabetes mellitus, a condition that may shorten life ex-
pectancy by up to 15 years.1 Atherosclerosis accounts for
about 80% of all deaths, of which roughly three-quarters
are attributable to coronary artery disease and the
remainder to cerebrovascular or peripheral vascular
events. As the prevalence of diabetes is estimated to
double by the year 2025, the burden of cardiovascular
disease associated with this condition will dramatically
increase.2 Of particular concern is the observation that
although over the last two decades cardiovascular mor-
tality has considerably declined a similar trend has not
been observed among diabetic patients.3 Pathologic and
angiographic studies support the notion that diabetic
patients have more diffuse and advanced coronary artery
disease than non-diabetics.4 In addition to coronary dis-
ease, diabetic cardiovascular involvement is character-
ized by higher prevalence of hypertension, heart failure,
peripheral vascular and cerebrovascular disease, and
nephropathy.
In the setting of non-ST-segment elevation acute
coronary syndromes (ACS), diabetes was found to be an
independent predictor of mortality.5 In addition, this
condition has been associated with worse outcomes fol-
lowing both coronary artery bypass grafting (CABG)6 and
percutaneous coronary intervention (PCI).7 The purpose
of this review is to summarize relevant biologic and
metabolic abnormalities, adjunctive treatments, and
outcomes of diabetic patients undergoing PCI, in
particular in the setting of ACS.
* Correspondence to: Eric J. Topol, MD, Department of Cardiovascular
Medicine, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave,
Cleveland, OH 44195, USA. Tel: +1 216 445 9493; fax: +1 216 445 9595
E-mail address: topole@ccf.org (E.J. Topol).
European Heart Journal (2004) 25, 190–198
0195-668X/04/$ - see front matter © 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
doi:10.1016/j.ehj.2003.10.027
Cardiovascular impact of biologic and
metabolic diabetic abnormalities
Several biological and metabolic abnormalities may con-
fer vulnerability to diabetic individuals for cardiovascular
events and potentially influence the outcomes following
revascularization (Fig. 1). One putative pathway is the
oxidation of amino groups by glucose, which ultimately
results in the formation of advanced glycation end-
products (AGE).8 Processes induced by augmented AGE
production include endothelial dysfunction, subendothe-
lial cellular proliferation and matrix expression, cytokine
release, macrophage activation, and expression of
adhesion molecules.8,9 Diabetic endothelial dysfunction
may be caused by a variety of additional factors including
hyperglycaemia, increased free fatty acid, altered
lipoproteins, insulin resistance, and hypertension.10,11
Prothrombotic state
The observation that diabetic patients have a hyper-
coagulable state is based both on the increased risk of
thrombotic events and on laboratory abnormalities. An
angioscopic study performed in ACS patients revealed
that plaque ulceration and intracoronary thrombus was
more frequent among diabetic patients that among
nondiabetics.12 Similarly, the incidence of thrombus was
found to be higher in atherectomy specimens from
patients with diabetes than in those of non-diabetic
counterparts.13 Diabetic individuals have increased
platelet activation and aggregation to shear stress and
platelet agonists.14 Increased levels of procoagulant
agents such as fibrinogen, tissue factor, von Willebrand
factor, platelet factor 4, factor VII, and decreased con-
centrations of endogenous anticoagulants such as protein
C and antithrombin III have been documented.15 Elevated
levels of plasminogen activator inhibitor-1 (PAI-1) may
impair endogenous tissue plasminogen activator-
mediated fibrinolysis.16 Finally, platelets of diabetic in-
dividuals are larger and have an increased numbers of
glycoprotein (GP) IIb/IIIa receptors per platelet.17
Despite the evidence of a prothrombotic diabetic state,
the exact mechanisms linking characteristics laboratory
findings to the initiation and progression of the athero-
sclerotic process remain elusive.
Inflammatory state
Inflammation has been related not only to acute cardio-
vascular events but also to initiation and progression of
atherosclerosis.18 The final pathway of many acknowl-
edged cardiovascular risk factors including diabetes ap-
pears to be the inducement of an inflammatory state,
which may be exaggerated in the setting of ACS. Although
we commonly consider white blood cells to be the prin-
cipal mediators of inflammation, the key role of platelets
has recently been demonstrated.19,20 Among other,
platelets are the primary source of the circulating/
soluble form of CD40 ligand (sCD40L), a protein that is
among the most important triggers of the cascade of
inflammatory cytokines and adhesion molecules, there-
fore linking inflammation and thrombosis.21
The interaction between the diabetes and inflam-
mation appears particularly complex.22 Although it is
plausible that metabolic disturbances associated with
this condition trigger vascular inflammation, the con-
verse may also be true. Accordingly, C-reactive protein
(CRP) was shown to independently predict the risk of
Fig. 1 Selected factors potentially affecting coronary artery disease (CAD) progression and/or outcomes following percutaneous coronary intervention
(PCI) among diabetic patients. hs-CRP=high-sensitivity C-reactive protein; IL-6=interleukin-6; VCAM-1=vascular sell adhesion molecule-1;
ICAM-1=intracellular adhesion molecule-1; sCD40L=soluble CD40 ligand; TNF-=tumour necrosis factor-; TSP-1=thrombospondin-1; RAGE=receptor for
advanced glycation end-products (AGE); GP=glycoprotein; TF=tissue factor; vWF=von Willebrand factor; PAI-1=plasminogen activator inhibitor-1; LV=left
ventricular; PPAR-=peroxisome proliferator-activated receptor-.
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later developing type 2 diabetes.23 Inflammatory par-
ameters elevated in diabetes include CRP, Il-6, tumour
necrosis factor alfa (TN), and sCD40L (Fig. 1).24.25 In
addition, this condition is associated with an increased
expression of adhesion molecules such as endothelial
(E)-selectin, serum vascular cell adhesion molecule-1
(VCAM-1) and intracellular adhesion molecule-1 (ICAM-
1).26 The link between inflammation and outcome can be
outlined among other by the observations that elevation
of high-sensitivity CRP, interleukin-6 (IL-6), or serum
VCAM-1 have been associated with increased mortality in
patients with coronary artery disease.27 The morphologi-
cal substrate of increased vascular inflammatory activity
can be derived by an analysis of coronary atherectomy
specimen of ACS patients, showing that tissue from dia-
betic patients exhibited a larger content of lipid-rich
atheroma and a more pronounced macrophage infil-
tration compared with specimen of nondiabetics.13
Percutaneous coronary intervention
While in-hospital and 30-day outcomes after PCI in dia-
betic patients are comparable to those of nondiabet-
ics,7,28 large-scale registries have shown that diabetes
remained in recent years an independent predictor of
long-term mortality and need for repeat revasculariz-
ation.7,29 Underlying mechanisms that may be related to
this inferior outcome include endothelial dysfunction,
prothrombotic state, greater propensity for restenosis
and negative vascular remodelling, increased protein
glycosylation and vascular matrix deposition. These
mechanisms appear to be potentiated by hyperglycaemia
and hyperinsulinaemia.30
Although, the placement of intracoronary stent
reduced the incidence of restenosis, diabetic patients
remained at higher risk for subsequent target vessel
revascularization (TVR) compared with nondiabetics.31
Nevertheless, the Do Tirofiban and ReoPro Give similar
Efficacy outcomes Trial (TARGET) demonstrated that
modern PCI, based on stenting and administration of
multiple antiplatelet agents, substantially improved out-
comes in this high-risk patient population.32 The TARGET
trial randomized patients at the time of stent-based PCI
to the GP IIb/IIIa antagonists tirofiban or abciximab in
addition to aspirin, clopidogrel, and periprocedural un-
fractionated heparin. When compared with non-diabetic
patients (n=3692), those with diabetes (n=1117) had simi-
lar 30-day event rates (Table 1). No difference in major
adverse cardiac events (MACE) at 6 months was observed
among the two groups, though diabetic patients had
more TVR (10.3% vs 7.8%, P=0.008) and higher mortality
(1.7% vs 0.9%, P=0.019) than non-diabetic patients. At 1
year, a trend towards increased mortality in the diabetic
group persisted (2.5% vs 1.6%, P=0.056). Although the
mortality data are concerning, the overall low event
rates observed in the TARGET trial demonstrates that in
diabetic patients with suitable coronary anatomy stent-
based PCI with triple antiplatelet therapy performs sat-
isfactorily. The low TVR rate reproduced on a larger scale
the single digit event rate (8.1%) observed among dia-
betic patients randomized to the abciximab-stent arm
(n=162) of the Evaluation of Platelet IIb/IIIa Inhibitor for
Stenting (EPISTENT) trial.33
Restenosis
Restenosis in diabetic patients is characterized by height-
ened proliferative response and increased vascular
matrix deposition. Mechanisms that may play a role in-
clude the interaction of the receptor for AGE (RAGE) and
its ligand, the peroxisome proliferator-activated recep-
tor (PPAR)- and thrombospondin-1 (TSP-1). RAGE, a
multiligand member of the immunoglobulin superfamily
of cell surface molecules, is expressed at low levels in
homeostasis but is upregulated at the site of vascular
injury, particularly within the expanding neointima.34
Animal studies have shown that blockade of RAGE re-
sulted in significantly decreased neointimal prolifer-
ation, migration, and expression of extracellular matrix
proteins.34 Similar findings were described in the RAGE
null mice.34 With respect to diabetes, RAGE have been
shown to be over-expressed after balloon injury in the
Table 1 Clinical outcomes patients undergoing percutaneous coronary intervention in the TARGET trial according to diabetic
status.32 Reproduced with permission
Time Event Diabetes No diabetes P
n=1117 n=3692
30 days Death 4 (0.4%) 18 (0.5%) 0.577
Non-fatal MIa 59 (5.3%) 237 (6.4%) 0.174
Death/MI 62 (5.5%) 248 (6.7%) 0.172
Urgent TVRb 5 (0.4%) 31 (0.8%) 0.191
Death/MI/urgent TVR 65 (5.8%) 261 (7.1%) 0.153
6 months Death 19 (1.7%) 32 (0.9%) 0.019
Non-fatal MI 72 (6.4%) 278 (7.5%) 0.231
Death/MI 88 (7.9%) 298 (8.1%) 0.824
Any TVR 115 (10.3%) 287 (7.8%) 0.008
Death/MI/TVR 182 (16.3%) 519 (14.1%) 0.082
1 year Death 28 (2.5%) 60 (1.6%) 0.056
aMI=myocardial infarction.
bTVR=target vessel revascularization.
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Zucker rat model and again blockade of RAGE/ligand
interaction significantly reduced vascular smooth muscle
cell proliferation and neointimal formation.35
Thrombospondin-1 (TSP-1) is a multifunctional protein
that interacts with a variety of matrix proteins and cell
surface receptors and among other induces vascular
smooth muscle cell proliferation and prevents endo-
thelial cell growth.36 The clinical relevance of this mol-
ecule can be derived from a genetic link demonstrated
between TSP-1 and premature atherosclerosis.37 Re-
cently, an increased expression of this protein in the
vascular wall of diabetic Zucker rats has been observed,
potentially linking diabetes, atherogenesis, and
accelerated restenosis.38
Early invasive versus conservative strategy
The role of early revascularization with either CABG or
PCI in diabetic patients with stable symptoms is currently
being tested in the Bypass Angioplasty Revascularization
Investigation (BARI)-2D.39 In the setting of non-ST-
segment elevation ACS, the positive impact of an early
invasive strategy among diabetics can be derived from
subgroup analyses of large-scale randomized trials. The
Fragmin and Fast Revascularisation during InStability in
Coronary artery disease (FRISC II) study randomized with
a 2×2 factorial design around 2500 patients to an invasive
or conservative strategy and unfractionated heparin or
dalteparin.40 Allocation to the invasive strategy was as-
sociated with a significant 22% reduction in death or
myocardial infarction (MI) at 6 months. Among diabetic
patients the relative risk reduction was similar but, due
to higher events rates, the absolute benefit was greater
(6.2%) compared with non-diabetics (2.3%). At 1 year,
diabetic patients undergoing early invasive therapy had a
38% reduction in the relative risk of death (7.7% vs
12.5%), albeit not reaching statistical significance due to
the small sample size (n=299).41
In the Treat Angina with Aggrastat and Determine Cost
of Therapy with an Invasive or Conservative Strategy
(TACTICS)-TIMI 18 trial,42 an early (i.e., within 48 h)
invasive strategy was associated with a significant 22%
reduction in the relative risk of death, MI, or re-
hospitalization for ACS at 6 months compared with an
early conservative strategy.42 All patients were treated
with aspirin, clopidogrel and tirofiban. Diabetic patients
had a greater benefit than non-diabetics from the early
invasive assessment both in terms of absolute (7.6%
and 1.8%, respectively) and relative 6-months event
reduction (27% and 13%, respectively) (Fig. 2).
Therefore, an early invasive assessment and if appro-
priate revascularization should be considered the strat-
egy of choice for diabetic patients with ACS. The question
how early should coronary angiography be performed has
no definitive answer. Within a small (n=131) randomized
trial, The Value of First Day Angiography/Angioplasty In
Evolving Non-ST segment Elevation Myocardial Infarction:
An Open Multicenter Randomized Trial (VINO), same day
(mean 6.2 h) angiography and if needed revascularization
was very effective compared with a conservative strategy
(6-month death or MI rate 6.2% and 22.3%, respectively;
P<0.001).43 Similarly, the Intracoronary Stenting with
Antithrombotic Regimen COOLing-off (ISAR-COOL) study
found a benefit of an immediate invasive strategy with an
average time to catheterization of 2 h compared with a
delayed invasive strategy (3–5 days) despite aggressive
antithrombotic treatment (i.e., aspirin, clopidogrel, tiro-
fiban, and unfractionated heparin). At 30 days the death
or MI rate was 5.9% in the immediate angiography group
and 11.6% among delayed assessment group.44 Impor-
tantly, the difference in the MI rate was entirely due to
events occurring prior to revascularization. Although
data specifically relating to diabetic patients are missing,
these findings suggest that despite potent platelet inhi-
bition it is rational to proceed with the earliest cardiac
catheterization.
Coronary artery bypass surgery in acute
coronary syndromes
The only randomized comparison between CABG with PCI
in patients with ACS is the Percutaneous Coronary Inter-
vention Versus Coronary Artery Bypass Graft Surgery for
patients with Medically Refractory Myocardial Ischemia
and Risk Factors for Adverse Outcomes with Bypass (AW-
SOME) trial.45 This study enrolled patients with medically
refractory unstable angina and at high-risk for CABG.
Among 2431 patients identified, 454 were considered
acceptable for both PCI and CABG, 1650 patients were
not deemed to be candidate for both therapies and
entered a physician-directed registry, and the 327 who
were considered candidate for both treatment but re-
fused randomization entered a patient-choice registry.
Overall diabetes prevalence was 31%. The respective
CABG and PCI 3-year survival rate for diabetic patients
were 72% and 81% for randomized patients (Fig. 3), 85%
and 89% for patient-choice registry patients, and 73% and
71% for the physician-directed registry patients.46 None
of the differences was statistically significant. These
results should be interpreted with caution, since from
both a surgical (left internal mammary artery used as
arterial conduit in 70% of cases) and an interventional
Fig. 2 Event rates at 6 months (death, myocardial infarction, or re-
hospitalization for acute coronary syndromes) in the TACTICS trial42
according to diabetes status.
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perspective (stents used in 54% and GP IIb/IIIa antagon-
ists in 11% of cases) the way patients were revascularized
in the study may not comply with current standards.
Nevertheless, CABG and PCI appear to be comparable
options for diabetic patients with ACS and the choice of
revascularization should be made individually based
on coronary anatomy, ventricular function, age, and
comorbidities.
Adjunctive pharmacologic treatment
Clopidogrel
The Clopidogrel in Unstable Angina to Prevent Recurrent
Events (CURE) trial randomized patients with ACS primar-
ily medically managed to aspirin or aspirin and clopidog-
rel. Diabetic patients (n=2840) derived only a modest
benefit from the combined treatment for 3 to 12 months
(death, MI, or stroke rate 14.2% vs 16.7%; P=ns) (Fig. 4).
Among patients undergoing PCI the benefit of the com-
bined antiplatelet therapy was somehow less marked
(relative risk 0.77) among diabetic patients compared
with non-diabetics (RR 0.66).47 The Clopidogrel for the
Reduction of Events During Observation (CREDO) trial
addressed a broader patient population, namely individ-
uals referred for a planned PCI or deemed to be at high
likelihood for requiring PCI.48 Patients were randomized
to a loading dose of clopidogrel followed by 12-month
therapy or no loading dose and clopidogrel treatment for
1 month. Among 560 diabetic patients, the benefit of
pre-treatment/prolonged clopidogrel therapy was mod-
est compared to the one observed among 1556 non-
diabetics (relative risk reduction 11% and 33%,
respectively).48 Nevertheless, clopidogrel should be
administered, preferably prior to coronary angiography,
in addition to aspirin to all diabetic patients with ACS
unless contraindicated.
Glycoprotein IIb/IIIa receptor antagonists
Despite increased baseline platelet aggregability, the
administration of abciximab has been shown to achieve a
similar degree of platelet inhibition among diabetic and
non-diabetic patients undergoing PCI.49 Intravenous GP
IIb/IIIa receptor inhibitors and intracoronary stents have
markedly reduced the early hazard in diabetic patients
undergoing PCI. In the EPISTENT trial abciximab halved
the risk of death, MI, or urgent revascularization at 30
days among stented patients with diabetes (from 12.1%
to 5.6%).50 The observed event rate was comparable to
that of abciximab-treated non-diabetic patients (5.2%). A
pooled analysis of the early abciximab trials demon-
strated a survival benefit at 1 year among diabetic
patients receiving the GP IIb/IIIa inhibitors compared
with placebo (mortality 4.5% vs 2.5%; P=0.031).51
While the overall impact of GP IIb/IIIa receptor inhibi-
tors in the medical management of non-ST-segment
elevation ACS has been modest,52 a mortality benefit has
been detected among diabetic patients. The meta-
analysis of the diabetic populations (n=6458) enrolled in
the six large-scale GP IIb/IIIa inhibitor ACS trials detected
a 26% mortality reduction associated with the use of
these agents at 30 days compared with placebo, from
6.2% to 4.6% (P=0.007) (Fig. 5). These findings were
reinforced by a statistically significant interaction be-
tween treatment and diabetic status. Glycoprotein IIb/
IIIa receptor inhibition was associated with similar
proportionate reduction in mortality for patients treated
with insulin and those on diet or oral hypoglycaemic
drugs. Even more striking was the benefit among diabetic
patients undergoing PCI. In this group of patients 30-day
mortality was reduced by 70%, from 4.0% to 1.2%
(P=0.002) (Fig. 6).
Further studies are needed to define whether the
preferential benefit observed with the administration of
these potent platelet inhibitors is related to diabetes-
associated conditions such as increased platelet acti-
vation, heightened inflammation, or to more diffuse
atherosclerosis with subsequent propensity for microvas-
cular embolization. Even without elucidation of the
mechanism, the data are compelling enough that the
administration of GP IIb/IIIa inhibitors should be consid-
ered standard of care for all diabetic patients presenting
with ACS. With respect to whether one agent may be
preferable over another in diabetic patients, subgroup
analysis of the TARGET trial demonstrated that the small-
molecule tirofiban and the antibody fragment abciximab
led to overall similar outcomes among patients undergo-
ing PCI.32 In particular, no difference was observed in this
thus far unique head-to-head comparison in terms of TVR
or late mortality, suggesting that the non-GP IIb/IIIa
properties of abciximab do not translate into a long-term
clinical benefit among diabetic patients.
GPIIb/IIIa receptor antagonists: still necessary in
the clopidogrel era?
In ACS patients, GP IIb/IIIa receptor antagonists have
been shown to be most effective within high risk groups
such as troponin positive, patients undergoing PCI, and
those with high clinical risk score.52,53 The same may not
true for clopidogrel, which conferred in the CURE trial
similar benefit across the spectrum of patient risk54
Fig. 3 Long-term survival among diabetic patients with acute coronary
syndromes randomized to percutaneous coronary intervention (PCI) or
coronary artery bypass surgery (CABG) in the AWSOME trial.46 Reproduced
with permission.
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revascularization strategies (Fig. 4).47 Importantly, the
preferential benefit of GP IIb/IIIa receptor inhibitors
among diabetic patients, both in the setting of PCI33 and
ACS55 could not be replicated with clopidogrel. Finally,
the excellent results obtained among diabetic patients
undergoing PCI in the TARGET trial were obtained with
triple antiplatelet therapy (i.e., aspirin, clopidogrel pre-
treatment, and GP IIb/IIIa antagonists).32 Recently, a
provocative preliminary report suggested that among
patients receiving 600 mg clopidogrel >2 h prior to the
intervention abciximab may nor confer additional ben-
efit.56 However, this study targeted low-risk patients and
both ACS patients and diabetics on insulin were excluded.
Therefore, triple antiplatelet regimen should be consid-
ered state-of-the art for diabetic patients with ACS.
Combination of GP IIb/IIIa receptor inhibitors
and low-molecular-weight heparin
The Aggrastat to Zocor (A-to-Z) study was the first clini-
cal trial powered to address clinical endpoint assessing
the use of low-molecular-weight heparin (LMWH) and GP
IIb/IIIa receptor inhibitors in non-ST-elevation ACS. In
addition to aspirin and tirofiban patients were random-
ized enoxaparin or weight-adjusted unfractionated
heparin. About 60% of the almost 4000 patients enrolled
Fig. 4 Impact on the combined end-point of death, myocardial infarction, or stroke of clopidogrel given for 3–12 months vs placebo according to clinical
risk stratification or diabetes status in the CURE trial65 and in the subgroup of patients who underwent percutaneous coronary intervention during index
hospitalization (PCI CURE).47 All patients received aspirin. CI=confidence interval; clop=clopidogrel; interm=intermediate.
Fig. 5 Odds ratio with 95% confidence intervals (CI) and corresponding P-values for treatment effect on 30-day mortality among diabetic patients with
acute coronary syndromes. Values to left of 1.0 indicate a survival benefit of platelet glycoprotein IIb/IIIa inhibition (IIb/IIIa).55 Reproduced with
permission.
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underwent early angiography. Overall, the two strategies
were equivalent in terms of 7-day death, MI, or refrac-
tory ischaemia, with a trend towards more bleeding in
the enoxaparin group.57 The ischaemic event rates in
diabetics did not differ among the two strategies. More
information on the safety and efficacy of enoxaparin in
ACS patients undergoing early invasive assessment will be
gathered in the ongoing Superior Yield of the New Strat-
egy of Enoxaparin, Revascularization, and Glycoprotein
IIb/IIIa inhibitors (SYNERGY) trial,58 which is comparing
enoxaparin to unfractionated heparin in 8000 patients
treated with early invasive strategy. Currently, both
heparin and LMWH should be considered antithrombotic
drugs of choice for diabetic patients with ACS undergoing
PCI.
Evolving therapies
Drug-eluting stents
The Randomized Study with the Sirolimus-Eluting Bx-
Velocity in the Treatment of Patients with de novo Native
Coronary Artery Lesions (SIRIUS)59 randomized 1101
patients to the sirolimus-eluting or bare metal stent and
confirmed the extraordinary reduction in restenosis pre-
viously reported in the Randomized Study with the
Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in
the Treatment of Patients with De Novo Native Coronary
Artery Lesions (RAVEL) trial.60 Among diabetic patients
enrolled in the SIRIUS trial (n=279), the sirolimus-eluting
stent was associated dramatic reduction in restenosis
compared with the bare stent (6.9% vs 22.3%, P<0.001).
The relative risk reduction for restenosis was of the same
magnitude among diabetic and non-diabetic patients
(70–80%). Due to higher event rates, the absolute benefit
derived within the diabetics population was greater than
among non-diabetics (154 and 111 restenosis prevented
per 1000 patients, respectively). Despite these impres-
sive findings, several observations suggest that diabetic
restenosis may be particularly resilient. In the SIRIUS trial
diabetes remained an independent predictors of poor
angiographic and clinical outcome among patients under-
going sirolimus-eluting stent implantation. In addition,
the restenosis rate among diabetic patients with lesions
>15 mm in vessels <2.5 mm was as high as 23.7%. Finally,
in the small group of patients treated with insulin (n=82),
the benefit in terms of restenosis of drug-elution was
modest (35.0% vs 50.0%; P=0.38).
The preliminary results the TAXUS IV trial have been
recently presented. In this study, 1314 patients with
single de novo lesions of 10–28 mm length and a refer-
ence vessel diameter of 2.50–3.75 mm were randomized
to slow-release paclitaxel-eluting stent or bare metal
stent. Angiographic follow-up at 9 months was available
for roughly three-quarters of the population enrolled in
the angiographic substudy. Among non-diabetic patients
(n=422), the binary restenosis rate in the analysis seg-
ment, defined as the stented segment plus 5 mm at the
proximal and distal edges of the stent, was 8.5% in the
paclitaxel-eluting stent group and 24.4% in the control
group (P<0.0001). The corresponding restenosis rates
for diabetic patients (n=136) were 6.4% and 34.5%
(P<0.0001). The inhibition of restenosis was profound and
achieved statistical significance among both diabetic
patients on oral hypoglycaemic drugs (n=89) (restenosis
rate 5.8% and 29.7%, respectively) and those on insulin
(n=47) (restenosis rate 7.7% and 42.9%, respectively).61
Clinical trials dedicated to diabetic patients are war-
ranted to address potential differences in efficacy among
agents used for local drug delivery.
Thiazolidindiones and RAGE/AGE suppression
All the major cells in the vasculature express the PPAR-
receptor, including endothelial cells, smooth muscle
cells, and monocytes/macrophages. Thiazolidindiones
Fig. 6 Odds ratio with 95% confidence intervals (CI) and corresponding P-values for treatment effect on 30-day mortality among diabetic patients with
acute coronary syndromes undergoing percutaneous coronary intervention. Values to left of 1.0 indicate a survival benefit of platelet glycoprotein IIb/IIIa
inhibition (IIb/IIIa).55 Reproduced with permission.
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(TZD) bind with high affinity to PPAR- receptor to en-
hance insulin-mediated glucose transport into adipose
tissue and skeletal muscle. Troglitazone, rosiglitazone,
and pioglitazone inhibit vascular smooth muscle cells
proliferation in vitro at drug levels therapeutic for anti-
diabetic therapy.62 In a small randomized trial, the
administration of troglitazone following coronary stent-
ing was associated with a reduction of restenosis on
intravascular ultrasound follow-up.63 However, the drug
was subsequently withdrawn from the market following
reports of severe hepatotoxicity. Recently, a positive
effect on restenosis has been reported with rosiglita-
zone.64 Among 93 diabetic patients, randomization to
TZD for 6 months post-PCI was associated with a signifi-
cant restenosis reduction compared with placebo (12% vs
47%, P<0.001). Clinical trials powered to assess restenosis
are needed before these agents can be recommended as
routine oral anti-diabetic drug therapy post-PCI.
Based on the previously described animal studies
showing striking neointimal suppression after vessel in-
jury associated with the suppression of the RAGE/AGE
complex both in the mice and in Zucker rats,34,35 this
interaction is the next logic target for restenosis preven-
tion, particularly in diabetics. Currently, studies are
being performed in pigs and efforts are being made to
produce a small molecule RAGE inhibitor.
Conclusions
Inflammation and a prothrombotic state are key patho-
physiologic mechanisms of diabetes-related coronary dis-
ease. In the setting of ACS diabetic patients are at higher
risk for subsequent cardiovascular events but at the same
time derive greater benefit from aggressive therapy than
the non-diabetic counterparts. The mainstays of acute-
phase therapy include triple antiplatelet therapy (i.e.,
aspirin, clopidogrel, and GP IIb/IIIa receptor antagonist),
heparin or LMWH, early invasive assessment and, if ap-
propriate, stent-based PCI. Coronary artery bypass graft-
ing may be a valid alternative in patients with complex
coronary anatomy, particularly in the setting of impaired
left ventricular function. Despite dramatic reduction in
restenosis conferred by drug-eluting stents, diabetic
patients remain at increased risk for repeat revascular-
ization. Therefore, more efforts are needed both in
terms of local drug elution as well as systemic pharmaco-
logic therapies to further contain the excessive neo-
intimal proliferation that characterizes the diabetic
response to vascular injury.
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